IMMX Immix Biopharma Forecast, Technical & Fundamental Analysis
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications... Show more
IMMX is expected to report earnings to fall 2.17% to -17 cents per share on September 02
Q2'26
Est.
$-0.18
Q1'26
Beat
by $0.03
Q4'25
Missed
by $0.08
Q3'25
Missed
by $0.08
Q2'25
Missed
by $0.01
The last earnings report on May 07 showed earnings per share of -18 cents, beating the estimate of -21 cents. With 661.11K shares outstanding, the current market capitalization sits at 748.92M.
A.I.dvisor indicates that over the last year, IMMX has been loosely correlated with ARQT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMX jumps, then ARQT could also see price increases.
IMMX saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for IMMX moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 45 similar instances where the indicator exited the overbought zone. In of the 45 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IMMX moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
IMMX broke above its upper Bollinger Band on July 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 16, 2026. You may want to consider a long position or call options on IMMX as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IMMX just turned positive on June 15, 2026. Looking at past instances where IMMX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
IMMX moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMMX crossed bullishly above the 50-day moving average on June 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMX advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 161 cases where IMMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.881) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). IMMX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (434.181).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
